Literature DB >> 2717001

One-year MR imaging follow-up of patients with multiple sclerosis under cortisone therapy.

D Uhlenbrock1, E Herbe, D Seidel, W Gehlen.   

Abstract

Twenty patients with relapsing/remitting course of MS were studied four times with MR imaging over the course of one year. First MR was undertaken during the acute relapse, afterwards patients were given cortisone therapy for four to six weeks. The second MR study followed 4-6 weeks after the first, the patients at this time being in remission. The third MR study was carried out 4 months after the first, the last scan one year after the first. The total number of lesions varied, though not greatly, over the whole follow-up, but there was an influence of the clinical course of MS on the pattern of lesions in MR imaging, mostly in respect to the number of confluences and the size of the lesions. Follow-up over one year showed that the inflammatory process produced an increase in the number of plaques, independent of the fact that most patients stayed in remission. A delayed effect of the cortisone therapy on the size, number, and confluence of plaques is suggested whilst clinical signs improved in most cases immediately after the beginning of drug therapy. Independent of the clinical course of the disease in some cases plaques previously seen vanished and others appeared in one and the same examination.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2717001     DOI: 10.1007/BF00342020

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  25 in total

Review 1.  Steroid therapy in multiple sclerosis. Point of view.

Authors:  R Troiano; S D Cook; P C Dowling
Journal:  Arch Neurol       Date:  1987-08

2.  Magnetic resonance imaging in multiple sclerosis: results in 32 cases.

Authors:  J A Jackson; D R Leake; N J Schneiders; L A Rolak; G R Kelley; J J Ford; S H Appel; R N Bryan
Journal:  AJNR Am J Neuroradiol       Date:  1985 Mar-Apr       Impact factor: 3.825

3.  MR imaging in multiple sclerosis: comparison with clinical, CSF, and visual evoked potential findings.

Authors:  D Uhlenbrock; D Seidel; W Gehlen; H K Beyer; J Haan; E Dickmann; T Zeit; E Herbe
Journal:  AJNR Am J Neuroradiol       Date:  1988 Jan-Feb       Impact factor: 3.825

4.  Magnetic resonance imaging: serial observations in multiple sclerosis.

Authors:  M A Johnson; D K Li; D J Bryant; J A Payne
Journal:  AJNR Am J Neuroradiol       Date:  1984 Sep-Oct       Impact factor: 3.825

5.  The initial diagnosis of multiple sclerosis: clinical impact of magnetic resonance imaging.

Authors:  S S Gebarski; T O Gabrielsen; S Gilman; J E Knake; J T Latack; A M Aisen
Journal:  Ann Neurol       Date:  1985-05       Impact factor: 10.422

6.  [Significance of magnetic resonance tomography in disseminated encephalomyelitis].

Authors:  K Baum; W Schörner; E Becker; H Bräu; W Girke; R Felix
Journal:  Nervenarzt       Date:  1985-12       Impact factor: 1.214

7.  Magnetic resonance in multiple sclerosis.

Authors:  G Scotti; G Scialfa; A Biondi; L Landoni; D Caputo; C L Cazzullo
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

8.  MR imaging of multiple sclerosis: comparison with clinical and CT examinations in 74 patients.

Authors:  J J Sheldon; R Siddharthan; J Tobias; W A Sheremata; K Soila; M Viamonte
Journal:  AJR Am J Roentgenol       Date:  1985-11       Impact factor: 3.959

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Magnetic resonance imaging and other techniques in the diagnosis of multiple sclerosis.

Authors:  H S Kirshner; S I Tsai; V M Runge; A C Price
Journal:  Arch Neurol       Date:  1985-09
View more
  1 in total

Review 1.  The pathogenesis of multiple sclerosis. Additional considerations.

Authors:  C M Poser
Journal:  J Neurol Sci       Date:  1993-04       Impact factor: 3.181

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.